Impact of different ANCA serotypes on the long-term outcome of ANCA-associated vasculitis patients

References

• Walker BS, Peterson LK, Koening C, et al. Performance of MPO–ANCA and PR3–ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(6):1. doi: 10.1016/j.autrev.2022.103100.
   Web of Science ®Google Scholar
• Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–11. doi: 10.1056/NEJMoa1108735.
   PubMed Web of Science ®Google Scholar
• Unizony S, Villarreal M, Miloslavsky EM, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166–1169. doi: 10.1136/annrheumdis-2015-208073.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Fu X, Harkness T, et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology. 2020;59(9):2308–2315. doi: 10.1093/rheumatology/kez589.
   PubMed Web of Science ®Google Scholar
• Murosaki T, Sato T, Akiyama Y, et al. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol. 2017;27(1):95–101. doi: 10.1080/14397595.2016.1192760.
   PubMed Web of Science ®Google Scholar
• Hong Y, Shi P, Liu X, et al. Distinction between MPO–ANCA and PR3–ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study. Clin Rheumatol. 2019;38(6):1665–1673. doi: 10.1007/s10067-019-04458-9.
   PubMed Web of Science ®Google Scholar
• Li Z-Y, Chang D-Y, Zhao M-H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center: relapse and treatment resistance in AAV. Arthritis Rheumatol. 2014;66(7):1920–1926. doi: 10.1002/art.38621.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bao H, Liu Z, et al. Risk factors for renal survival in Chinese patients with myeloperoxidase–ANCA-associated GN. Clin J Am Soc Nephrol. 2017;12(3):417–425. doi: 10.2215/CJN.06200616.
   PubMed Web of Science ®Google Scholar
• Huang L, Shen C, Zhong Y, et al. The association of neutrophil-to-lymphocyte ratio with all-cause mortality in Chinese patients with MPO–ANCA associated vasculitis. Clin Exp Med. 2020;20(3):401–408. doi: 10.1007/s10238-020-00629-0.
   PubMed Web of Science ®Google Scholar
• Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018;19(1):138. doi: 10.1186/s12882-018-0933-2.
   PubMedGoogle Scholar
• Liu S, Han L, Liu Y, et al. Clinical significance of MPO–ANCA in eosinophilic granulomatosis with polyangiitis: experience from a longitudinal Chinese cohort. Front Immunol. 2022;13:885198. doi: 10.3389/fimmu.2022.885198.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi: 10.1002/art.37715.
   PubMed Web of Science ®Google Scholar
• Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366–1383. doi: 10.1002/art.41773.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–1832. doi: 10.1136/ard.2008.101279.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) Cohort. Medicine. 2011;90(1):19–27. doi: 10.1097/MD.0b013e318205a4c6.
   PubMed Web of Science ®Google Scholar
• Wójcik K, Masiak A, Jeleniewicz R, et al. Association of antineutrophil cytoplasmic antibody (ANCA) specificity with the demographic and clinical characteristics of patients with ANCA-associated vasculitides. Pol Arch Intern Med. 2022;132(3):16187. doi: 10.20452/pamw.16187.
   PubMedGoogle Scholar
• Weiner M, Bjørneklett R, Hrušková Z, et al. Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant. 2018;34(2):301–308. doi: 10.1093/ndt/gfy106.
   Web of Science ®Google Scholar
• Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol. 2014;41(7):1366–1373. doi: 10.3899/jrheum.131038.
   PubMed Web of Science ®Google Scholar
• Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–3462. doi: 10.1002/art.34562.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Springer J. Editorial: classifying antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides according to ANCA type or phenotypic diagnosis: salt or pepper? Arthritis Rheumatol. 2016;68(12):2837–2840. doi: 10.1002/art.39860.
   PubMed Web of Science ®Google Scholar
• Xie G, Roshandel D, Sherva R, et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA–DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum. 2013;65(9):2457–2468. doi: 10.1002/art.38036.
   PubMedGoogle Scholar
• Merkel PA, Xie G, Monach PA, et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 2017;69(5):1054–1066. doi: 10.1002/art.40034.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Kobayashi S, Hashimoto H, et al. Association of HLA-DRB1*0901-DQB1*0303 haplotype with microscopic polyangiitis in Japanese. Genes Immun. 2006;7(1):81–84. doi: 10.1038/sj.gene.6364262.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Kobayashi S, Kawasaki A, et al. Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis. J Rheumatol. 2003;30(7):1534–1540.
   PubMed Web of Science ®Google Scholar
• Kawasaki A, Hasebe N, Hidaka M, et al. Protective role of HLA-DRB1*13:02 against microscopic polyangiitis and MPO–ANCA-positive vasculitides in a Japanese population: a case-control study. PLOS One. 2016;11(5):e0154393. doi: 10.1371/journal.pone.0154393.
   PubMed Web of Science ®Google Scholar
• Wang H-Y, Cui Z, Pei Z-Y, et al. Risk HLA class II alleles and amino acid residues in myeloperoxidase–ANCA-associated vasculitis. Kidney Int. 2019;96(4):1010–1019. doi: 10.1016/j.kint.2019.06.015.
   PubMed Web of Science ®Google Scholar
• Monti S, Craven A, Klersy C, et al. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. Rheumatology. 2021;60(2):617–628. doi: 10.1093/rheumatology/keaa215.
   PubMed Web of Science ®Google Scholar
• McGovern D, Williams SP, Parsons K, et al. Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology. 2020;59(5):1076–1083. doi: 10.1093/rheumatology/kez388.
   PubMed Web of Science ®Google Scholar
• de Lind van Wijngaarden RAF, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17(8):2264–2274. doi: 10.1681/ASN.2005080870.
   PubMed Web of Science ®Google Scholar
• Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–494. doi: 10.1136/ard.2010.137778.
   PubMed Web of Science ®Google Scholar
• Haris Á, Polner K, Arányi J, et al. Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis. BMC Nephrol. 2017;18(1):76. doi: 10.1186/s12882-017-0491-z.
   PubMedGoogle Scholar
• Hilhorst M, Wilde B, van Paassen P, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant. 2013;28(2):373–379. doi: 10.1093/ndt/gfs428.
   PubMed Web of Science ®Google Scholar
• Tanna A, Guarino L, Tam FWK, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant. 2015;30(7):1185–1192. doi: 10.1093/ndt/gfu237.
   PubMed Web of Science ®Google Scholar
• Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143(9):621–631. doi: 10.7326/0003-4819-143-9-200511010-00005.
   PubMed Web of Science ®Google Scholar
• Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177–1188. doi: 10.1016/j.kint.2018.07.020.
   PubMed Web of Science ®Google Scholar
• Brilland B, Boud’hors C, Copin M-C, et al. Assessment of renal risk score and histopathological classification for prediction of end-stage kidney disease and factors associated with change in eGFR after ANCA-glomerulonephritis diagnosis. Front Immunol. 2022;13:834878. doi: 10.3389/fimmu.2022.834878.
   PubMed Web of Science ®Google Scholar
• Steinberg AW, Wechsler ME, Fernández Pérez ER. Trends in antineutrophil cytoplasmic autoantibody-associated vasculitis-related mortality in the United States, 1999 to 2017. Ann Intern Med. 2020;172(2):160–163. doi: 10.7326/M19-1564.
   PubMed Web of Science ®Google Scholar
• Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842–852. doi: 10.1681/ASN.V95842.
   PubMed Web of Science ®Google Scholar
• Mahr A, Girard T, Agher R, et al. Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology. 2001;40(5):492–498. doi: 10.1093/rheumatology/40.5.492.
   PubMed Web of Science ®Google Scholar
• Hruskova Z, Casian A, Konopasek P, et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol. 2013;42(3):211–214. doi: 10.3109/03009742.2012.754939.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis. 2008;67(7):1004–1010. doi: 10.1136/ard.2007.071936.
   PubMed Web of Science ®Google Scholar
• Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German Vasculitis Center over four decades. Arthritis Rheum. 2011;63(1):257–266. doi: 10.1002/art.27763.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908–2918. doi: 10.1002/art.23800.
   PubMedGoogle Scholar
• Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(2):542–548. doi: 10.1002/art.33361.
   PubMed Web of Science ®Google Scholar
• Hara A, Wada T, Sada K, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis in Japan: a nationwide, prospective cohort study. J Rheumatol. 2018;45(4):521–528. doi: 10.3899/jrheum.170508.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Segelmark M, Smith R, et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2017;44(10):1468–1475. doi: 10.3899/jrheum.160909.
   PubMed Web of Science ®Google Scholar
• Rathmann J, Jayne D, Segelmark M, et al. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology. 2021;60(6):2745–2754. doi: 10.1093/rheumatology/keaa699.
   PubMed Web of Science ®Google Scholar